Zapping resistant tumors to keep lung cancer at bay
NCT ID NCT03667820
Summary
This study is testing if adding precise, high-dose radiation (SABR) to the standard drug osimertinib can better control advanced lung cancer with specific genetic changes (EGFR mutations). The goal is to target and destroy tumors that don't fully respond to the drug alone, hoping to delay the cancer's return. All participants continue taking osimertinib long-term after the radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.